Online inquiry

IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10001MR)

This product GTTS-WQ10001MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGF23 gene. The antibody can be applied in Dermatological genetic disorders research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_020638.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8074
UniProt ID Q9GZV9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10001MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9441MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ12748MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ3380MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ10928MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ4776MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ237MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ5119MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ8030MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW